EnglishConvinced by the development program that was launched by the young start-up and by the dynamic team that was installed, and following the obtention of a 450 000 € aid from Oseo / Languedoc-Roussillon Region, SurgiMab’s investors decided to consolidate their initial engagement, allowing the company to seure its R&D program up to the start of the clinical trials for its first molecule.
The realization of this investment demonstrated the capacity of the founding team to federate all necessary actors for a quick development of SurgiMab’s fluorescent conjugates. “These seeding funds, added to the institutional help and the initial investment from our partners allows to foresee the first clinical assays in 2013, to propose our technology to patients as quickly and directly as possible” says Françoise Cailler, President of SurgiMab.
In order to finalize the clinical studies that are compulsory for the development of its products, the company will prepare a new funds raising at the beginning of 2013.